A pivotal phase 3 clinical trial published in the New England Journal of Medicine demonstrates significant efficacy advantages for long-acting injectable antiretroviral therapy over conventional daily oral medications in treating HIV patients. The LATITUDE study compared long-acting cabotegravir and rilpivirine administered via injection against standard daily oral antiretroviral therapy, with results showing meaningful differences in treatment outcomes over a 48-week period.
The injectable regimen achieved a regimen failure rate of 22.8%, substantially lower than the 41.2% failure rate observed in the daily oral therapy group. This performance advantage is particularly relevant for HIV patients who face challenges with medication adherence, as the injectable formulation eliminates the need for daily pill-taking. The safety profiles between the two treatment approaches were comparable, with both groups experiencing similar rates and types of adverse events.
The findings, published through ACTG (AIDS Clinical Trials Group), represent a significant advancement in treatment options for people living with HIV. The results provide clinical evidence supporting the use of long-acting injectables as an alternative to daily oral regimens, potentially expanding therapeutic choices for patients and healthcare providers managing HIV treatment protocols.